Exploring the synergy between tumor microenvironment modulation and STING agonists in cancer immunotherapy
2024
Exploring the synergy between tumor microenvironment modulation and STING agonists in cancer immunotherapy
publication
Evidence: moderate
Author Information
Author(s): Qi Xiaoyan, Cheng Cheng, Zhang Dawei, Yu Zongjiang, Meng Xiangwei
Primary Institution: Zibo Central Hospital, Zibo, China
Hypothesis
Combining STING agonists with tumor microenvironment modulation can enhance cancer immunotherapy effectiveness.
Conclusion
The combination of TME modulation with STING agonists shows promise for improving cancer treatment outcomes by overcoming immunosuppressive barriers.
Supporting Evidence
- The STING pathway can enhance immune responses against tumors.
- TME modulation can shift macrophages from an immunosuppressive to a pro-inflammatory state.
- Combining STING agonists with therapies targeting Tregs can improve anti-tumor immunity.
- MDSCs are a significant barrier to effective immunotherapy and can be targeted to enhance STING efficacy.
- Clinical trials are exploring combinations of STING agonists with immune checkpoint inhibitors.
Takeaway
This study looks at how changing the environment around tumors can help new treatments work better against cancer.
Limitations
The study discusses challenges such as the heterogeneous nature of the TME and potential systemic inflammation from STING activation.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website